We describe a fully automated assay for determining effective heparin activity in plasma, based on heparin-catalyzed inhibition of Factor Xa (EC 3.4.21.6) by antithrombin Ill (AT Ill). Residual Factor Xa is determined kinetically by the Du Pont aca#{174} discrete clinical analyzer with a chromogenic substrate and is inversely related to heparin activity. Because the test plasma is the sole source of AT Ill, the assay result is dependent on AT Ill activity and reflects effective rather than total heparin activity. The assay range is 20-1200 USP units/L, and the assay shows equivalent sensitivity to standard and low-molecular-mass heparins. Within-run reproducibility (CV) is 1.6% at 390 units/L. There was no interference from common blood components or drugs. Results agreed well with those by the Coatest#{174} hepann kit (Kabi) adapted to the Cobas-Bio#{174} analyzer (r = 0.85, n = 122).
Heparin, a naturally occurring polymeric mucopolysaccharide with anticoagulant and antithrombotic properties, is the drug of choice for treating venous thrombosis. It also can be used to treat disseminated intravascular coagulation, as prophylaxis against postoperative thrombosis, to facilitate initiation of oral anticoagulant therapy, and to maintain blood fluidity during extracorporeal circulation (1, 2) . Laboratory monitoring of heparin therapy is desirable to ensure that an appropriate antithrombotic effect is obtained, while guarding against bleeding complications of an overdosage. Unfortunately, assays currently used for monitoring are hampered by the variable nature of the drug: inherent polymer chain heterogeneity, multiple in vivo biological activities, interindividual variation in drug sensitivity, and method of manufacture (3). Two of the most commonly used assays are the activated partial thromboplastmn time and the activated clotting time. Both of these are evaluations of heparin's overall activities throughout the entire coagulation system, and results are affected by components in plasma not related to heparin (4) .
An alternative approach is to assay for heparin by exploiting its catalysis by antithrombin ffi (AT ifi) inhibition of coagulation enzymes, particularly thrombin
(EC 3.4.21.5)
and Factor Xa (EC 3.4.21.6) (5). This improves assay specificity and allows for a reproducible system with biochemically defined assay reagents. Use of chromogenic substrates for enzyme quantification gives good sensitivity, decreases nonspecific interferences, and facilitates assay automation (6) .
In developing an assay of heparmn, one must decide whether to measure total or effectiveheparmnactivity. Addition of exogenous AT ifi decreases assay dependency on AT ifi and yields the total available heparin activity in the sample (7). However, patients with decreased activity of AT E. I. ifi express only a portion of the total heparin activity in vivo. Other modulators of heparin and AT ifi may also regulate in vivo heparmn activity. When the test sample is the only source of AT ifi, then the assay is sensitive to these physiological factors and measures the effective heparin activity, which potentially is more clinically useful than a measurement of total activity (8).
We describe a fully automated assay for effective heparmn activity in plasma, implemented with the aca discrete clinical analyzer(E. I. du Pont de Nemours & Co., Inc., Wilmington, DE 19898). The assay is based on the heparin catalyzed inhibition of Factor X9 by AT ifi via the reaction sequence:
Factor XaAT ifi (inactive) + Factor Xa (residual)
The residual Factor Xa then hydrolyzes the chromogemc substrate methoxycarbonyl-o-cyclohexylglycyl-glycyl-arginyl-p-nitroaniline (CHGGA) to release p-mtroaniline. The rate of p-nitroaniline appearance is nonlinearly related to the sample's effective heparin activity. Pooled normal human plasma was purchased from a blood bank and storedat -70 #{176}C. Human AT ifi-depleted plasma was obtainedfrom Dr. F. A. Ofosu, Canadian Red Cross Society, Toronto, Canada (9) .
Materials and Methods

Reagents
We used phosphate buffer (150 mmol/L, pH 7.80 at 37#{176}C) from DuPont. All other reagents were of the highest quality For clinical studies, we used Du Pont "HEPRN" heparin analytical test packs and the aca ifi discrete clinical analyzer.
Heparin Test Procedure
The aca analyzer transfers 300 L of citrate-treated test plasma and 4.700 mL of phosphate buffer into a heparin analytical test pack. The plasma and buffer are warmed to 37 #{176}C for 75 s, then bovine Factor Xa is added. The heparmn and AT ifi in the test plasma react with the Factor Xa for 187.5 s, after which the substrate CHGGA is added. The amount of residual Factor Xa is determined by the rate at which p-mtroaniline is released from the substrate. The rate at 405 nm is computed from two absorbance measurements, made 17.07 s apart, the first 29 s after the addition. This result is converted to effective heparin activity (units/L) by using a calibration equation previously stored in the instrument (aca Ill, N, or V analyzers) or by using specialized graph paper supplied with the test packs (aca II analyzer).
Calibration Standards
We calibrated by using either a freshly thawed normal human plasma supplemented with concentrated heparin solution or a rehydrated Du Pont heparin calibrator. The Du Pont calibrator, a lyophilized preparation of standard porcine intestinal mucosal heparin in a normal human plasma base,is packaged as a set of three standards with nominal contents of 100, 400, and 1000 unitsfL, as determined by comparison with the anti-Factor Xa activity of the USP heparin standard (lot Ki). The effective heparin activity (unitslL) is calculated from the logit linearization function
where Y is the computed reaction rate in mA/mm and X is the effective heparin activity. The coefficients C2, C3, and C4 are specific for a given pack lot and C0 and C1 are determined during assay calibration.
Results and Discussion
Optimization Studies
CHGGA. We assessed several commercially available selective chromogenic substrates for Factor X with respect to enzyme kinetic parameters (Km, V) and solubility. CHGGA was determined to have kinetic properties at least equivalent to those of other substrates, and superior solubility (>10 mmoIJL in water). Buffers were assessedfor their effects on Km and V (Table 1 ) accordingto a previously described experimental protocol (10). We selected phosphate buffer because of its inhibition of calcium-dependent reactions, its low Km, and itsavailability for use with the aca.
Because activity of residual Factor X5 is maximal in plasma containing no heparin, we optimized substrate concentration with respect to reaction rate by using normal human plasma as the test sample (Figure 1) . Our use of a concentration of 493 MmoI/L in the pack provided sufficient substrate so as not to compromise the rate measurement. The final concentration of CHGGA in the pack is approximately fourfold greater than the Km for bovine Factor X5. Iii the absence of plasma, as much as 10 kilounits of heparin per liter had no influence on the reaction rate.
Factor X0. Both human and bovine derived Factor Xa were evaluated for assay sensitivity. The calibration curves (Figure 2) clearly show that bovine Factor Xa is more reactive than human Factor Xa towards the human AT ifiheparin complex, in agreement with earlier reports (11). In addition, the Km of the bovine enzyme is half that of the may be present in samples from patients who are undergoing extracorporeal circulation. Such samples can be diluted fourfold with normal human plasma to bring them within the assay range, but the assay values will reflect total rather than effective heparin activity, owing to the inclusion of added AT ifi. This is appropriate in this case because: (a) the heparmn activity is being measured to compute a post-surgical dosage of protamine sulfate for neutralization of total heparin and (b) hemodilution during extracorporeal circulation causes gross underestimation of the effective heparin activity.
Reproducibility.
Estimates of within-run and day-to-day reproducibility are given in Table 2 for several activities of heparin. Equivalent reproducibility was seen whether calibrators or patients' samples were the test samples.
Interferences. We investigated 16 common drugs and plasma components (Table 3) for interference with the assay in samples containing 400 units of heparin per liter. None showed clinically significant interference.
Sensitivity to ATIII. A desirable feature of this assay is its simultaneous sensitivity toward heparin and AT ifi. After assaying AT ifi-depleted plasma supplemented with increasing amounts of purified AT ifi and heparin, we calcuhuman enzyme, which decreases the substrate requirement for the assay.
We optimized Factor Xa activity by using overall assay sensitivity (steepness of slope) and reproducibility at heparim concentrations of 500 and 800 units/L as response variables. As shown in Figure 3 , increased enzyme activity led to an increase in the standardcurve slope, particularly at lower activities of heparin. Reproducibility is poorest at high heparmnactivity in packs containing the least amount of Factor Xa. Above 0.7 U of Factor X5 per pack, the assay reproducibility is insensitive to the activity of Factor X5. To maximize assay reproducibility and minimize reagent cost, we set the final Factor Xa activity at 0.7 U per pack.
pH. Variation in reaction pH causes opposing changes in assay sensitivity and rate of CHGGA hydrolysis. Increasing the pH leads to an increased rate of CHGGA hydrolysis by Factor Xa but decreases the overall assay sensitivity (AT ifi inhibition of Factor Xa); the reverse is true at lower pH values. Using phosphate buffer at pH 7.80 provides nearmaximal assay sensitivity while maintaining acceptable enzyme activity.
Anaiytical Performance
Standard curve. Figure 4 shows a typical standard curve for both a standard and a low-molecular-mass heparin 2. lated the analytical recovery of heparmnby using calibration curves generated with heparin calibrator containing a "normal" amount of AT 111(100% of the AT Ill present in normal human plasma) ( Figure 5 ). At 0% AT Ill, the assay is insensitive to heparin; i.e., analytical recovery of heparin is 0%. Heparin recovery increases with increasing AT ifi activity, with recovery being 100% when the AT ifi activity in normal human plasma is approximately 100%. Effect of variation in heparin preparations. Recognition of variability in heparmn preparations as a result of biosynthesis and methods of purification has prompted a recommendation that assay standard curves be prepared from the same lot of heparin that is used for the patient's treatment (13). However, this is difficult to put into practice for hospitals with more than one heparin lot in inventory, and it hampers agreement on a generalized therapeutic range.
The anti-Factor Xa activity of the Du Pont heparin calibrator is referenced to the USP heparin standard (currently, lot K1). Thus, the use of this calibrator with the HEPRN test packs will provide consistent information on drug dosage. Figure 6 sununarizes the performance of various preparations from several major domestic heparin suppliers, as evaluated for bias between labeled drug activity and that determined by the Du Pont assay. (14) . The method is basedon inhibition of Factor Xa by heparin and AT Ill, and utilizes exogenous AT ifi to decrease the assay's dependency on endogenous AT ifi. The correlation statistics were: Du Pont heparin = 1.07 Coatest -30 unitsfL, S = 110 units/L, r = 0.85, range of heparin activities 0 to 950 USP unitsfL. The variation reflects the differential sensitivity of the two assays to endogenous AT ifi activity, the Coatest assay being less sensitive to endogenous AT ifi activity. For a subpopulation of 20 samples with AT ifi activity <90%, the correlation statistics were: DuPont heparin = 0.63 Coatest + 430 units/L. In summary, this fully automated, rapid assay for effective heparin activity in plasma, developed for the aca, shows excellent analytical performance. Unlike assays based on thrombin, this assay based on Factor Xa is sensitive to bOth standardand low-molecular-mass heparmns. The use of test plasma as the sole source of AT ifi results in measurements of effective heparin activity rather than of total heparin activity.
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